[1]
|
World Health Organization (2022, February 21) WHO Coronavirus Disease (COVID-19) Dashboard.
https://covid19.who.int/
|
[2]
|
Yurkovetskiy, L., Wang, X., Pascal, K.E., et al. (2020) Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell, 183, 739-751.E8. https://doi.org/10.1016/j.cell.2020.09.032
|
[3]
|
World Health Organization (n.d.) Tracking SARS-CoV-2 Variants.
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
|
[4]
|
GISAID (2022) Tracking of Variants. https://www.gisaid.org/hcov19-variants/
|
[5]
|
PANGO (2022) PANGO Lineages: Latest Epidemiological Lineages of SARS-CoV-2.
https://cov-lineages.org/global_report_B.1.1.529.html
|
[6]
|
Chen, J., Wang, R., Gilby, N.B., et al. (2022) Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. Journal of Chemical Information and Modeling, 62, 412-422.
https://doi.org/10.1021/acs.jcim.1c01451
|
[7]
|
吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14-19.
|
[8]
|
Khandia, R., Singhal, S., Alqahtani, T., et al. (2022) Emergence of SARS-CoV-2 Omicron (B.1.1.529) Variant, Salient Features, High Global Health Concerns and Strategies to Counter It Amid Ongoing COVID-19 Pandemic. Environmental Research, 209, Article ID: 112816. https://doi.org/10.1016/j.envres.2022.112816
|
[9]
|
王康泓. SARS-CoV-2感染机制分析与COVID-19治疗药物研究进展[J]. 生命科学研究, 2020, 24(6): 442-451.
|
[10]
|
Gao, G.F. and Wang, L. (2021) COVID-19 Expands Its Territories from Humans to Animals. China CDC Weekly, 3, 855-858. https://doi.org/10.46234/ccdcw2021.210
|
[11]
|
Mishra, A., Kumar, N., Bhatia, S., et al. (2021) SARS-CoV-2 Delta Variant among Asiatic Lions, India. Emerging Infectious Diseases, 27, 2723-2725. https://doi.org/10.3201/eid2710.211500
|
[12]
|
Ferasin, L., Fritz, M., Ferasin, H., et al. (2021) Infection with SARS-CoV-2 variant, B.1.1.7 Detected in a Group of Dogs and Cats with Suspected Myocarditis. Veterinary Record, 189, e944. https://doi.org/10.1002/vetr.944
|
[13]
|
Wei, C., Shan, K.J., Wang, W., et al. (2021) Evidence for a Mouse Origin of the SARS-CoV-2 Omicron Variant. Journal of Genetics and Genomics, 48, 1111-1121. https://doi.org/10.1016/j.jgg.2021.12.003
|
[14]
|
McCallum, M., Czudnochowski, N., Rosen, L.E., et al. (2022) Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement. Science, 375, 864-868. https://doi.org/10.1126/science.abn8652
|
[15]
|
周玉霞, 王彩红, 姚晓文, 等. 免疫抑制人群与SARS-CoV-2变异相关性研究进展[J]. 海南医学院学报, 2022(5): 321-325.
|
[16]
|
Jensen, B., Luebke, N., Feldt, T., et al. (2021) Emergence of the E484K Mutation in SARS-CoV-2-Infected Immunocompromised Patients Treated with Bamlanivimab in Germany. The Lancet Regional Health—Europe, 8, Article ID: Article ID: 100164. https://doi.org/10.1016/j.lanepe.2021.100164
|
[17]
|
Choi, B., Choudhary, M.C., Regan, J., et al. (2020) Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 383, 2291-2293. https://doi.org/10.1056/NEJMc2031364
|
[18]
|
Avanzato, V.A., Matson, M.J., Seifert, S.N., et al. (2020) Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell, 183, 1901-1912.e9.
https://doi.org/10.1016/j.cell.2020.10.049
|
[19]
|
Truong, T.T., Ryutov, A., Pandey, U., et al. (2021) Increased Viral Variants in Children and Young Adults with Impaired Humoral Immunity and Persistent SARS-CoV-2 Infection: A Consecutive Case Series. EBioMedicine, 67, Article ID: 103355. https://doi.org/10.1016/j.ebiom.2021.103355
|
[20]
|
He, Y., Ma, W., Dang, S., et al. (2022) Possible Recombination between Two Variants of Concern in a COVID-19 Patient. Emerging Microbes & Infections, 11, 552-555. https://doi.org/10.1080/22221751.2022.2032375
|
[21]
|
Minskaia, E., Hertzig, T., Gorbalenya, A.E., et al. (2006) Discovery of an RNA Virus 3’→5’ Exoribonuclease That Is Critically Involved in Coronavirus RNA Synthesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 5108-5113. https://doi.org/10.1073/pnas.0508200103
|
[22]
|
McCarthy, K.R., Rennick, L.J., Nambulli, S., et al. (2021) Recurrent Deletions in the SARS-CoV-2 Spike Glycoprotein Drive Antibody Escape. Science, 371, 1139-1142. https://doi.org/10.1126/science.abf6950
|
[23]
|
Papanikolaou, V., Chrysovergis, A., Ragos, V., et al. (2022) From Delta to Omicron: S1-RBD/S2 Mutation/Deletion Equilibrium in SARS-CoV-2 Defined Variants. Gene, 814, Article ID: 146134.
https://doi.org/10.1016/j.gene.2021.146134
|
[24]
|
CoVariants (2022) Variant: 21K (Omicron). https://covariants.org/variants/21K.Omicron
|
[25]
|
Koley, T., Kumar, M., Goswami, A., et al. (2022) Structural Modeling of Omicron Spike Protein and Its Complex with Human ACE-2 Receptor: Molecular Basis for High Transmissibility of the Virus. Biochemical and Biophysical Research Communications, 592, 51-53. https://doi.org/10.1016/j.bbrc.2021.12.082
|
[26]
|
Wu, L., Zhou, L., Mo, M., et al. (2022) SARS-CoV-2 Omicron RBD Shows Weaker Binding Affinity than the Currently Dominant Delta Variant to Human ACE2. Signal Transduction and Targeted Therapy, 7, Article No. 8.
https://doi.org/10.1038/s41392-021-00863-2
|
[27]
|
Lupala, C.S., Ye, Y., Chen, H., et al. (2022) Mutations on RBD of SARS-CoV-2 Omicron Variant Result in Stronger Binding to Human ACE2 Receptor. Biochemical and Biophysical Research Communications, 590, 34-41.
https://doi.org/10.1016/j.bbrc.2021.12.079
|
[28]
|
Khan, A., Waris, H., Rafique, M., et al. (2022) The Omicron (B.1.1.529) Variant of SARS-CoV-2 Binds to the hACE2 Receptor More Strongly and Escapes the Antibody Response: Insights from Structural and Simulation Data. International Journal of Biological Macromolecules, 200, 438-448. https://doi.org/10.1016/j.ijbiomac.2022.01.059
|
[29]
|
Omotuyi, O., Olubiyi, O., Nash, O., et al. (2022) SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but Not Convalescent Monoclonal Antibody. Computers in Biology and Medicine, 142, Article ID: 105226. https://doi.org/10.1016/j.compbiomed.2022.105226
|
[30]
|
Mannar, D., Saville, J.W., Zhu, X., et al. (2022) SARS-CoV-2 Omicron Variant: Antibody Evasion and Cryo-EM Structure of Spike Protein-ACE2 Complex. Science, 375, 760-764. https://doi.org/10.1126/science.abn7760
|
[31]
|
Fang, F.F. and Shi, P.Y. (2022) Omicron: A Drug Developer’s Perspective. Emerging Microbes & Infections, 11, 208-211. https://doi.org/10.1080/22221751.2021.2023330
|
[32]
|
Zahradník, J., Marciano, S., Shemesh, M., et al. (2021) SARS-CoV-2 Variant Prediction and Antiviral Drug Design Are Enabled by RBD In Vitro Evolution. Nature Microbiology, 6, 1188-1198.
https://doi.org/10.1038/s41564-021-00954-4
|
[33]
|
Sharma, V., Rai, H., Gautam, D.N.S., et al. (2022) Emerging Evidence on Omicron (B.1.1.529) SARS-CoV-2 Variant. Journal of Medical Virology, 94, 1876-1885. https://doi.org/10.1002/jmv.27626
|
[34]
|
Singh, A., Steinkellner, G., Köchl, K., et al. (2021) Serine 477 Plays a Crucial Role in the Interaction of the SARS-CoV-2 Spike Protein with the Human Receptor ACE2. Scientific Reports, 11, Article No. 4320.
https://doi.org/10.1038/s41598-021-83761-5
|
[35]
|
Han, P., Li, L., Liu, S., et al. (2022) Receptor Binding and Complex Structures of Human ACE2 to Spike RBD from Omicron and Delta SARS-CoV-2. Cell, 185, 630-640.e10. https://doi.org/10.1016/j.cell.2022.01.001
|
[36]
|
Dejnirattisai, W., Huo, J., Zhou, D., et al. (2022) SARS-CoV-2 Omicron-B.1.1.529 Leads to Widespread Escape from Neutralizing Antibody Responses. Cell, 185, 467-484.e15. https://doi.org/10.1016/j.cell.2021.12.046
|
[37]
|
Zhao, H., Lu, L., Peng, Z., et al. (2022) SARS-CoV-2 Omicron Variant Shows Less Efficient Replication and Fusion Activity When Compared with Delta Variant in TMPRSS2-Expressed Cells. Emerging Microbes & Infections, 11, 277-283. https://doi.org/10.1080/22221751.2021.2023329
|
[38]
|
Bojkova, D., Widera, M., Ciesek, S., et al. (2022) Reduced Interferon Antagonism but Similar Drug Sensitivity in Omicron Variant Compared to Delta Variant of SARS-CoV-2 Isolates. Cell Research, 32, 319-321.
https://doi.org/10.1038/s41422-022-00619-9
|
[39]
|
Meng, B., Abdullahi, A., Ferreira, I.A.T.M., et al. (2022) Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Tropism and Fusogenicity. Nature, 603, 709-714.
|
[40]
|
Xia, X. (2020) Extreme Genomic CpG Deficiency in SARS-CoV-2 and Evasion of Host Antiviral Defense. Molecular Biology and Evolution, 37, 2699-2705. https://doi.org/10.1093/molbev/msaa094
|
[41]
|
Viswanathan, T., Arya, S., Chan, S.H., et al. (2020) Structural Basis of RNA cap Modification by SARS-CoV-2. Nature Communications, 11, Article No. 3718. https://doi.org/10.1038/s41467-020-17496-8
|
[42]
|
Yan, L., Yang, Y., Li, M., et al. (2021) Coupling of N7-Methyltransferase and 3’-5’Exoribonuclease with SARS-CoV-2 Polymerase Reveals Mechanisms for Capping and Proofreading. Cell, 184, 3474-3485.E11.
https://doi.org/10.1016/j.cell.2021.05.033
|
[43]
|
Mu, J., Xu, J., Zhang, L., et al. (2020) SARS-CoV-2-Encoded Nucleocapsid Protein Acts as a Viral Suppressor of RNA Interference in Cells. Science China Life Sciences, 63, 1413-1416. https://doi.org/10.1007/s11427-020-1692-1
|
[44]
|
Fu, Y.Z., Wang, S.Y., Zheng, Z.Q., et al. (2021) SARS-CoV-2 Membrane Glycoprotein M Antagonizes the MAVS-Mediated Innate Antiviral Response. Cellular & Molecular Immunology, 18, 613-620.
https://doi.org/10.1038/s41423-020-00571-x
|
[45]
|
Xia, H., Cao, Z., Xie, X., et al. (2020) Evasion of Type I Interferon by SARS-CoV-2. Cell Reports, 33, Article ID: 108234. https://doi.org/10.1016/j.celrep.2020.108234
|
[46]
|
Chen, K., Xiao, F., Hu, D., et al. (2020) SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production. Viruses, 13, Article No. 47. https://doi.org/10.3390/v13010047
|
[47]
|
Li, J.Y., Liao, C.H., Wang, Q., et al. (2020) The ORF6, ORF8 and Nucleocapsid Proteins of SARS-CoV-2 Inhibit Type I Interferon Signaling Pathway. Virus Research, 286, Article ID: 198074.
https://doi.org/10.1016/j.virusres.2020.198074
|
[48]
|
Mu, J., Fang, Y., Yang, Q., et al. (2020) SARS-CoV-2 N Protein Antagonizes Type I Interferon Signaling by Suppressing Phosphorylation and Nuclear Translocation of STAT1 and STAT2. Cell Discovery, 6, Article No. 65.
https://doi.org/10.1038/s41421-020-00208-3
|
[49]
|
Cao, Z., Xia, H., Rajsbaum, R., et al. (2021) Ubiquitination of SARS-CoV-2 ORF7a Promotes Antagonism of Interferon Response. Cellular & Molecular Immunology, 18, 746-748. https://doi.org/10.1038/s41423-020-00603-6
|
[50]
|
马睿忆, 董晓婧, 肖霞, 等. SARS-CoV-2非结构蛋白1抑制Ⅰ型干扰素应答反应[J]. 国际病毒学杂志, 2021, 28(2): 116-119.
|
[51]
|
Polycarpou, A., Howard, M., Farrar, C.A., et al. (2020) Rationale for Targeting Complement in COVID-19. EMBO Molecular Medicine, 12, Article No. e12642. https://doi.org/10.15252/emmm.202012642
|
[52]
|
Noris, M., Benigni, A., Remuzzi, G. (2020) The Case of Complement Activation in COVID-19 Multiorgan Impact. Kidney International, 98, 314-322. https://doi.org/10.1016/j.kint.2020.05.013
|
[53]
|
Tian, W., Zhang, N., Jin, R., et al. (2020) Immune Suppression in the Early Stage of COVID-19 Disease. Nature Communications, 11, Article No. 5859. https://doi.org/10.1038/s41467-020-19706-9
|
[54]
|
Schmidt, F., Muecksch, F., Weisblum, Y., et al. (2021) Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant. medRxiv. https://doi.org/10.1101/2021.12.12.21267646
|
[55]
|
YangYang, Gong, X., Yang, L., et al. (2022) Regular and Booster Vaccination with Inactivated Vaccines Enhance the Neutralizing Activity against Omicron Variant both in the Breakthrough Infections and Vaccines. Journal of Infection, 84, 579-613. https://doi.org/10.1016/j.jinf.2022.01.004
|
[56]
|
Lu, L., Mok, B.W., Chen, L.L., et al. (2021) Neutralization of SARS-CoV-2 Omicron Variant by Sera from BNT162b2 or Coronavac Vaccine Recipients. Clinical Infectious Diseases. https://doi.org/10.1101/2021.12.13.21267668
|
[57]
|
Dejnirattisai, W., Shaw, R.H., Supasa, P., et al. (2022) Reduced Neutralisation of SARS-CoV-2 Omicron, B.1.1.529 Variant by Post-Immunisation Serum. Lancet, 399, 234-236. https://doi.org/10.1016/S0140-6736(21)02844-0
|
[58]
|
Kannan, S.R., Spratt, A.N., Sharma, K., et al. (2022) Omicron SARS-CoV-2 Variant: Unique Features and Their Impact on Pre-Existing Antibodies. Journal of Autoimmunity, 126, Article ID: 102779.
https://doi.org/10.1016/j.jaut.2021.102779
|
[59]
|
Hu, J., Peng, P., Cao, X., et al. (2022) Increased Immune Escape of the New SARS-CoV-2 Variant of Concern Omicron. Cellular & Molecular Immunology, 19, 293-295. https://doi.org/10.1038/s41423-021-00836-z
|
[60]
|
Wang, S.F., Tseng, S.P., Yen, C.H., et al. (2014) Antibody-Dependent SARS Coronavirus Infection Is Mediated by Antibodies against Spike Proteins. Biochemical and Biophysical Research Communications, 451, 208-214.
https://doi.org/10.1016/j.bbrc.2014.07.090
|
[61]
|
Smatti, M.K., Al Thani, A.A., Yassine, H.M. (2018) Viral-Induced Enhanced Disease Illness. Frontiers in Microbiology, 9, Article No. 2991. https://doi.org/10.3389/fmicb.2018.02991
|
[62]
|
Liu, Y., Soh, W.T., Kishikawa, J.I., et al. (2021) An Infectivity-Enhancing Site on the SARS-CoV-2 Spike Protein Targeted by Antibodies. Cell, 184, 3452-3466.E18. https://doi.org/10.1016/j.cell.2021.05.032
|
[63]
|
Simon-Loriere, E. and Schwartz, O. (2022) Towards SARS-CoV-2 Serotypes? Nature Reviews Microbiology, 20, 187-188. https://doi.org/10.1038/s41579-022-00708-x
|
[64]
|
Liu, L., Iketani, S., Guo, Y., et al. (2022) Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature, 602, 676-681. https://doi.org/10.1038/s41586-021-04388-0
|
[65]
|
Guigon, A., Faure, E., Lemaire, C., et al. (2022) Emergence of Q493R Mutation in SARS-CoV-2 Spike Protein during Bamlanivimab/Etesevimab Treatment and Resistance to Viral Clearance. Journal of Infection, 84, 248-288.
https://doi.org/10.1016/j.jinf.2021.08.033
|
[66]
|
Geurtsvan Kessel, C.H., Geers, D., Schmitz, K.S., et al. (2022) Divergent SARS CoV-2 Omicron-Reactive T- and B Cell Responses in COVID-19 Vaccine Recipients. Science Immunology, 7, eabo2202.
https://doi.org/10.1126/sciimmunol.abo2202
|
[67]
|
Bertoletti, A., Le Bert, N., Qui, M., et al. (2021) SARS-CoV-2-Specific T Cells in Infection and Vaccination. Cellular & Molecular Immunology, 18, 2307-2312. https://doi.org/10.1038/s41423-021-00743-3
|
[68]
|
Choi, S.J., Kim, D.U., Noh, J.Y., et al. (2022) T Cell Epitopes in SARS-CoV-2 Proteins Are Substantially Conserved in the Omicron Variant. Cellular & Molecular Immunology, 19, 447-448. https://doi.org/10.1038/s41423-022-00838-5
|
[69]
|
Grifoni, A., Sidney, J., Vita, R., et al. (2021) SARS-CoV-2 Human T Cell Epitopes: Adaptive Immune Response against COVID-19. Cell Host & Microbe, 29, 1076-1092. https://doi.org/10.1016/j.chom.2021.05.010
|
[70]
|
Gao, Y., Cai, C., Grifoni, A., et al. (2022) Ancestral SARS-CoV-2-Specific T Cells Cross-Recognize the Omicron Variant. Nature Medicine, 28, 472-476. https://doi.org/10.1038/d41591-022-00017-z
|
[71]
|
Sherina, N., Piralla, A., Du, L., et al. (2021) Persistence of SARS-CoV-2-Specific B and T Cell Responses in Convalescent COVID-19 Patients 6-8 Months after the Infection. Med, 2, 281-295.e4.
https://doi.org/10.1016/j.medj.2021.02.001
|
[72]
|
Fantini, J., Yahi, N., Colson, P., et al. (2022) The Puzzling Mutational Landscape of the SARS-2-Variant Omicron. Journal of Medical Virology, 94, 2019-2025. https://doi.org/10.1002/jmv.27577
|
[73]
|
Motozono, C., Toyoda, M., Zahradnik, J., et al. (2021) SARS-CoV-2 Spike L452R Variant Evades Cellular Immunity and Increases Infectivity. Cell Host & Microbe, 29, 1124-1136.e11. https://doi.org/10.1016/j.chom.2021.06.006
|
[74]
|
Mok, C.K.P., Cheng, S.M.S., Chen, C., et al. (2022) A RCT Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. American Journal of Respiratory and Critical Care Medicine, 205, 844-847. https://doi.org/10.1164/rccm.202111-2655le
|
[75]
|
Costa Clemens, S.A., Weckx, L., Clemens, R., et al. (2022) Heterologous versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single Blind, Randomised Study. Lancet, 399, 521-529.
https://doi.org/10.1016/S0140-6736(22)00094-0
|
[76]
|
Cao, Y., Hao, X., Wang, X., et al. (2022) Humoral Immunogenicity and Reactogenicity of CoronaVac or ZF2001 Booster after Two Doses of Inactivated Vaccine. Cell Research, 32, 107-109.
https://doi.org/10.1038/s41422-021-00596-5
|
[77]
|
王康泓, 丁崇正. SARS-CoV-2抗原表位分析及相关疫苗研发的进展与挑战[J]. 微生物学通报, 2021, 48(1): 241-252.
|
[78]
|
Krause, P.R., Fleming, T.R., Peto, R., et al. (2021) Considerations in Boosting COVID-19 Vaccine Immune Responses. Lancet, 398, 1377-1380. https://doi.org/10.1016/S0140-6736(21)02046-8
|
[79]
|
岳小林, 王雅葳, 王欣. 新型冠状病毒肺炎mRNA疫苗相关淋巴结病的研究现状[J]. 药物不良反应杂志, 2021, 23(11): 592-596.
|
[80]
|
Wolter, N., Jassat, W., Walaza, S., et al. (2022) Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study. Lancet, 399, 437-446.
https://doi.org/10.1016/S0140-6736(22)00017-4
|
[81]
|
Abdullah, F., Myers, J., Basu, D., et al. (2022) Decreased Severity of Disease during the First Global Omicron Variant Covid-19 Outbreak in a Large Hospital in Tshwane, South Africa. International Journal of Infectious Diseases, 116, 38-42. https://doi.org/10.1016/j.ijid.2021.12.357
|
[82]
|
Modes, M.E., Directo, M.P., Melgar, M., et al. (2022) Clinical Characteristics and Outcomes among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of, B.1.617.2 (Delta) and, B.1.1.529 (Omicron) Variant Predominance—One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. Morbidity and Mortality Weekly Report, 71, 217-223. https://doi.org/10.15585/mmwr.mm7106e2
|
[83]
|
Espenhain, L., Funk, T., Overvad, M., et al. (2021) Epidemiological Characterisation of the First 785 SARS-CoV-2 Omicron Variant Cases in Denmark, December 2021. Euro Surveill, 26, Article ID: 2101146.
https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101146
|
[84]
|
Brandal, L.T., MacDonald, E., Veneti, L., et al. (2021) Outbreak Caused by the SARS-CoV-2 Omicron Variant in Norway, November to December 2021. Euro Surveill, 26, Article ID: 2101147.
https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147
|
[85]
|
Kim, M.K., Lee, B., Choi, Y.Y., et al. (2022) Clinical Characteristics of 40 Patients Infected with the SARS-CoV-2 Omicron Variant in Korea. Journal of Korean Medical Science, 37, e31. https://doi.org/10.3346/jkms.2022.37.e31
|
[86]
|
Lopez, L., Sang, P.C., Tian, Y., et al. (2020) Dysregulated Interferon Response Underlying Severe COVID-19. Viruses, 12, 1433. https://doi.org/10.3390/v12121433
|
[87]
|
Chen, J. and Wei, G.W. (2022) Omicron, B.A.2 (B.1.1.529.2): High Potential to Becoming the Next Dominating Variant. Preprint. ArXiv, arXiv:2202.05031v1. https://doi.org/10.21203/rs.3.rs-1362445/v1
|
[88]
|
Desingu, P.A. and Nagarajan, K. (2022) Omicron, BA.2 Lineage Spreads in Clusters and Is Concentrated in Denmark. Journal of Medical Virology, 94, 2360-2364. https://doi.org/10.1002/jmv.27659
|
[89]
|
孙丹, 杨金燕, 夏婷婷, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究进展[J/OL]. 中华医院感染学杂志: 1-5.
https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=ZHYY2022050500W&uniplatform=NZKPT&v=yXnxOaaFz0JYxfn59cmAFggCl7dOYH5WuTcuLg4xRhd0n-XgLDq0ghztaFoQ1neC, 2022-02-11.
|
[90]
|
Ahmed, W., Bivins, A., Smith, W.J.M., et al. (2022) Detection of the Omicron (B.1.1.529) Variant of SARS-CoV-2 in Aircraft Wastewater. Science of the Total Environment, 820, Article ID: 153171.
https://doi.org/10.1016/j.scitotenv.2022.153171
|
[91]
|
Kirby, A.E., Welsh, R.M., Marsh, Z.A., et al. (2022) Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater—United States, November-December 2021. Morbidity and Mortality Weekly Report, 71, 103-105. https://doi.org/10.15585/mmwr.mm7103a5
|